New allergy shot aims to tame dust mite misery
NCT ID NCT04184895
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new biologic drug called ASP2390, given as a skin injection, in 28 adults with house dust mite allergies. The main goal is to check safety and how the immune system responds, not yet whether it works. If successful, it could lead to a new way to ease allergy symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASP2390 (a biologic given as a skin injection)
What this could lead to
If it works, this could point toward a new treatment for house dust mite allergies that reduces allergic reactions.
What could go wrong
This is a very early Phase 1 trial with only 28 people, focused on safety, not effectiveness. The treatment may not work or could cause side effects like injection-site reactions or allergic responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC TO HOUSE DUST MITES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site DE49001
Berlin, Germany
-
Site DE49002
Hanover, Germany